Flomax treats benign prostatic hyperplasia.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has obtained tentative US Food and Drug Administration (FDA) approval for the company's generic version of Flomax, a treatment of signs and symptoms of benign prostatic hyperplasia (BPH) made by Boehringer Ingelheim. Teva expects final approval when Flomax's patent expires in October 2009.
According to IMS sales data, brand Flomax has $1.3 billion in sales in the 12 months through September 2007.
Published by Globes [online], Israel business news - www.globes-online.com - on January 31, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008